BioSpace News Archive

QINLOCK Significantly Improved Progression-Free Survival and Showed Clinically Meaningful Overall Survival in Global INVICTUS Phase 3 Study

Reinforces PARP7 as a novel therapeutic target and that inhibition of PARP7 induces both antitumor immunity and cancer cell-intrinsic effects

Peptide-drug conjugates TH1902 and TH1904 show significant reduction in the formation of vasculogenic mimicry by targeting the sortilin receptor Curcumin shows increased anticancer activity when conjugated to proprietary peptide SORT1+ technology significantly widens therapeutic window of traditional cytotoxic cancer treatments

Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it will be presenting at Proactive One2One Virtual Investor Forum on June 23, 2020. Dr. Heman Chao, Chief Executive Officer of Helix is scheduled to present on Tuesday, June 23 rd at approximately 1:20pm Eastern Time. The presentation will be web

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, and Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced a global research and option agreement to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing and RNA technologies for neuromuscular diseases.

Poster details data from aTyr’s preclinical, domain specific Neuropilin-2 (NRP2) antibody program showing antibodies may increase sensitivity to chemotherapy in triple-negative breast cancer. SAN DIEGO, June 22, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a poster and audio presentation at the 2020 American Association for Cancer

Priority Health and Cigna announced they have formed a Strategic Alliance and will partner to make comprehensive health care coverage more affordable and accessible to Michigan employers, their employees and families.

The Lung Cancer Research Foundation (LCRF) today announced that Dr. Trudy Oliver has joined its Scientific Advisory Board.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the company will receive a $10 million milestone payment from Janssen Biotech, Inc. (Janssen) triggered under the Collaboration and License Agreement between the two companies. The milestone payment is associated with the first commercial sale in the European Union of Janssen’s

CRH Medical Corporation (the “Company” ) (TSX: CRH) (NYSE MKT: CRHM), announces that it completed an accretive transaction whereby the Company has acquired a 75% interest in Metro Orlando Anesthesia Associates, LLC (“Metro Orlando”), a gastroenterology (“GI”) anesthesia practice located in Orlando, Flor